Publication | Closed Access

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Neoadjuvant DabrafenibSurgical OncologyMedicineMelanomaPathologyBrafv600 Mutation-positive MelanomaDermatologyCancer TreatmentOncologyRadiation OncologyMolecular OncologyStage Iiib–c